CoChat

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion. Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells. Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits-including durable responses--to patients with different malignancies. However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature13988

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 1,974

Metadata

Authors
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S. K., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., Schumacher, T. N., Aebersold, R., Rammensee, H.-G., Melief, C. J. M., Mardis, E. R., Gillanders, W. E., Artyomov, M. N., & Schreiber, R. D.
Affiliations
  • Washington University in St. Louis (US)
  • German Cancer Research Center (DE)
  • ISA Pharmaceuticals (Netherlands) (NL)
  • The Netherlands Cancer Institute (NL)
  • Bristol-Myers Squibb (United States) (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Harvard University (US)
  • University of Zurich (CH)
  • Leiden University Medical Center (NL)
Corresponding author
Schreiber, Robert D.
Venue
Nature
Published
2014-11-26
Volume
515
Issue
7528
Pages
577-581
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2079018735
Cited by
1,974
References
48
Citations by year
2026: 58 · 2025: 94 · 2024: 123 · 2023: 145 · 2022: 174 · 2021: 216 · 2020: 206 · 2019: 203 · 2018: 194 · 2017: 190 · 2016: 195 · 2015: 165 · 2014: 8
FWCI
89.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
Funders
  • National Institutes of Health (5u01ca141541-02)
  • National Cancer Institute (P50CA101942, R01CA043059, U01-CA141541, R37CA043059, R01CA190700, P30CA016672, T32CA009547, P30CA091842)
  • National Institute of Allergy and Infectious Diseases (P01AI054456, R01AI091965)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
cancer immunotherapy, immune checkpoint blockade, anti-PD-1, anti-CTLA-4, CD8+ T cell responses, therapeutic vaccines, personalized cancer vaccines, tumor antigens, long peptide vaccine, tumor immunosuppression, tumor regression
MeSH terms
Animals, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Immunotherapy, Male, Sarcoma, Vaccines, Synthetic, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.